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The regulation of pancreatic β cell mass is a critical factor to help maintain normoglycemia during 
insulin resistance. Nutrient-sensing G protein-coupled receptors (GPCR) contribute to aspects of β 
cell function, including regulation of β cell mass. Nutrients such as free fatty acids (FFAs) contribute 
to precise regulation of β cell mass by signaling through cognate GPCRs, and considerable evidence 
suggests that circulating FFAs promote β cell expansion by direct and indirect mechanisms. Free 
Fatty Acid Receptor 2 (FFA2) is a β cell-expressed GPCR that is activated by short chain fatty acids, 
particularly acetate. Recent studies of FFA2 suggest that it may act as a regulator of β cell function. 
Here, we set out to explore what role FFA2 may play in regulation of β cell mass. Interestingly, Ffar2−/− 
mice exhibit diminished β cell mass at birth and throughout adulthood, and increased β cell death at 
adolescent time points, suggesting a role for FFA2 in establishment and maintenance of β cell mass. 
Additionally, activation of FFA2 with Gαq/11-biased agonists substantially increased β cell proliferation 
in in vitro and ex vivo proliferation assays. Collectively, these data suggest that FFA2 may be a novel 
therapeutic target to stimulate β cell growth and proliferation.
In response to states of chronic insulin resistance, pancreatic islets employ multiple compensatory responses in an 
attempt to maintain whole-body glucose homeostasis. These responses consist of enhanced insulin secretion as 
well as expansion of beta (β ) cell mass1. When an individual is unable to sustain these compensatory mechanisms, 
due to a confluence of genetic, environmental, and/or lifestyle factors, progression to Type 2 diabetes (T2D) can 
occur. The specific contribution of β cell mass deficits versus impaired β cell function in the progression to de facto 
T2D remains a matter of some debate2. However, several lines of evidence suggest that initial β cell loss (possibly 
occurring as early as the pre-diabetic phase) places increased secretory burden on the surviving β cells, leading 
to chronic β cell stress and further impairments in β cell function as a result of β cell exhaustion3–6. Along these 
lines, impaired pre- or postnatal development of β cells is suggested to predispose some individuals to T2D when 
exposed to aggravating factors such as obesity and insulin resistance2. This possibility is illustrated by studies in 
which factors such as genetic polymorphisms and fetal malnutrition have been shown to impair β cell mass and 
result in increased diabetes risk later in life7–10.
Consistent with these reports, the nutritional status of an individual is thought to be an important regulator 
of β cell mass. Multiple nutrients such as glucose, amino acids, and free fatty acids contribute to maintain precise 
regulation of β cell mass11. For example, evidence suggests that circulating levels of glucose and free fatty acids 
(FFA) can promote β cell expansion, although this remains a matter of some debate12. Additionally, nutrient 
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sensing via the gut may indirectly contribute to regulation of β cell mass by promoting GLP-1 secretion from 
intestinal L-cells, which in turn acts at the β cell to promote cell survival and proliferation. Many nutrients and 
nutrient-regulated factors exert their influence through G protein-coupled receptors (GPCRs), consistent with 
the well characterized ability of these receptors to regulate multiple aspects of β cell function and health, including 
glucose-stimulated insulin secretion (GSIS) and β cell survival and proliferation13. For example, chronic signal-
ing through Gα q/11 and Gα s by designer GPCRs enhanced β cell mass as a result of increased β cell proliferation 
and β cell hypertrophy14,15. In support of this observation, signaling via the Gα s-coupled GLP-1 receptor by the 
agonist Exendin-4 improves β cell function, potentiating GSIS and enhancing β cell replication and neogenesis16. 
Similarly, activation of Gα q/11-coupled receptors such as the M3 muscarinic and long chain free fatty acid recep-
tor FFA1 potentiate GSIS and have been suggested to promote β cell survival and proliferation13,17,18. In contrast, 
activation of Gα i/o19,20 or Gα z21 pathways inhibits β cell function and proliferation.
In addition to FFA1, multiple other FFA-sensing GPCRs have been identified in the β cell, and have garnered 
considerable interest as potential targets for the treatment of T2D in recent years22,23. Recently, our group and 
others have reported that islet expression of the short chain fatty acid receptor FFA2 is dynamically regulated in 
association with multiple models of insulin resistance, including pregnancy and diet-induced and genetic models 
of obesity and diabetes24–26. The endogenous ligands of FFA2, short chain fatty acids, are derived primarily from 
fermentation of dietary fiber by gut flora27, positioning FFA2 as one possible link between the gut microbiome 
and its host. These observations have led us to explore and describe a role for FFA2 in affecting crucial aspects of β 
cell biology. These studies revealed that FFA2 signaling can either stimulate GSIS via the Gα q/11 pathway or inhibit 
GSIS via Gα i/o28. Specifically, we found that two different classes of previously described FFA2 agonists, small car-
boxylic acids and phenylacetamide derivatives, demonstrated a bias toward activating Gα q/11 or Gα i/o pathways, 
respectively. Around the same time, two other groups published their findings, with McNelis et al. reporting dual 
coupling of FFA2 to Gα i/o and Gα q/11, with potentiation of GSIS mediated primarily by Gα q/1129. By contrast, Tang 
et al., observed solely Gα i/o signaling via FFA2, leading to inhibition of GSIS30. With respect to β cell mass, Tang 
et al., and McNelis et al. also reported conflicting findings. Whereas Tang et al. reported no differences in islet 
morphology between WT and Ffar2−/− mice30, McNelis et al. reported a defect in β cell mass expansion in 
response to insulin resistance as a result of Ffar2 deletion29. Because of the importance of β cell mass in T2D 
pathogenesis, here we sought to clarify a potential role for FFA2 in regulating β cell mass and proliferation, and to 
determine how biased signaling of FFA2 through Gα q/11 or Gα i/o may determine its effect on β cell mass.
Results
Genetic deletion of Ffar2 impairs postnatal β cell mass. In T2D, the loss of functional β cell mass 
is an important factor in disease-development31. As GPCRs have been described to contribute to β cell mass 
through their role in mediating β cell properties such as proliferation and apoptosis13–20, we examined the effect 
of Ffar2 deletion on β cell mass. Immunohistochemical (IHC) and morphometric analysis of normal chow (NC) 
fed Ffar2−/− male mice at 26 weeks revealed significantly decreased insulin positive area (relative to total pancre-
atic area), smaller average β cell area per islet, and decreased β cell mass compared to age matched, WT controls 
(Fig. 1a). Notably, we have also observed this phenotype in a separate study of 10–12 week old Ffar2−/− females32. 
To examine the influence of FFA2 in regulating adaptive β cell mass expansion in response to insulin resistance, 
we also assessed β cell mass in WT and Ffar2−/− mice at 26 weeks, following 20 weeks of high fat diet (HFD). 
Figure 1. Genetic deletion of Ffar2 impairs postnatal β cell mass. (a) β cell area, average β cell area per islet, 
and β cell mass of WT and Ffar2−/− mice. Adult mice were fed either normal chow (NC) or high fat diet  
(HFD) as indicated; β cell area is expressed as percent insulin positive area relative to total pancreatic area.  
(b) β to α cell ratio at each indicated time point. (c) Representative images of WT and Ffar2−/− islets at P21 and 
26 weeks. Scale bar = 20 μ m. Green: insulin, red: glucagon. For all experiments, n ≥ 3; white bars = WT, black 
bars = Ffar2−/−. * p < 0.05, * * p < 0.01 and * * * p < 0.001.
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Although the overall trend toward diminished β cell mass persisted in HFD-fed Ffar2−/− mice, β cell mass in 
Ffar2−/− islets did increase in response to HFD, suggesting that mice with deletion of Ffar2 retain some capacity 
for adaptive β cell mass expansion in response to HFD (Fig. 1a).
Given the diminished β cell mass in adult Ffar2−/− mice under normal diet conditions, we next examined β 
cell mass at younger ages, specifically, immediately postnatal (P1) and at 21 days (P21), to determine when the 
β cell mass phenotype became apparent. Interestingly, we observed significant reductions in the β cell area of 
Ffar2−/− mice at both ages, and marginally decreased β cell mass at P21, suggesting that impairments in β cell 
mass develop during the prenatal period in Ffar2−/− mice (Fig. 1a). Despite these impairments, overall islet archi-
tecture and α to β cell ratio was unaffected at each age examined (Fig. 1b,c).
Ffar2−/− islets demonstrate increased β cell death in vivo. To better understand the mechanism by 
which Ffar2 contributes to β cell mass, we next assessed β cell proliferation, as this is a major factor regulating 
postnatal β cell mass, and is modulated in part by GPCR signaling33. Using Ki67 immunostaining to assess β cell 
proliferation at early-postnatal (P1), adolescent (P21), and adult (10 weeks and 26 weeks) ages, we observed dra-
matically increased β cell proliferation in Ffar2−/− pancreata at P21 and a trend toward increased proliferation at 
10 weeks, but found no differences in β cell proliferation between WT and Ffar2−/− mice at P1 or 26 weeks on NC 
diet (Fig. 2a). Thus, these data do not suggest that impaired β cell proliferation is a primary mechanism leading to 
diminished β cell mass in Ffar2−/− pancreata.
Given these findings, we suspected that diminished β cell mass may stem from increased rates of β cell death 
in Ffar2−/− mice. Recent studies have reported that β cell death results in an increase in serum unmethylated 
preproinsulin DNA, the presence of which may serve as a reliable biomarker of β cell death34–37. We therefore 
analyzed the serum of WT and Ffar2−/− mice at P21 and 10 weeks of age by multiplex PCR and found a signif-
icantly higher unmethylation index in Ffar2−/− mice at both time points, indicating increased β cell death in 
Ffar2−/− mice (Fig. 2b); these findings were further supported by observations of increased cleaved caspase 3 
staining in Ffar2−/− islets at P21 and 10 weeks (Fig. 2c). Taken together, these data suggest that Ffar2 contributes 
to the prenatal establishment of β cell mass, and that deletion of Ffar2 results in increased postnatal β cell death, 
suggesting a role for FFA2 in supporting β cell survival.
Acetate does not promote FFA2 mediated β cell proliferation. As Gα q/11-coupled GPCRs are well 
known to mediate β cell proliferation15, we more directly examined whether FFA2 signaling can influence β cell 
proliferation using ex vivo studies with intact mouse islets from 10–12 week old WT and Ffar2−/− mice. Here, 
we did not observe any significant differences in the rate of proliferation between WT and Ffar2−/− β cells under 
untreated conditions, nor in response to the primary endogenous FFA2 ligand, acetate or the GLP-1 receptor ago-
nist, exendin 4, which is known to potently enhance β cell proliferation (Fig. 3a). It is noteworthy, however, that 
treatment with prolactin, which is also known to stimulate β cell proliferation, did not significantly enhance pro-
liferation in Ffar2−/− β cells (Fig. 3a)16,38. This observation is especially important in light of our recent findings 
that adaptive β cell mass expansion during pregnancy is compromised in Ffar2−/− female mice32, as this adaptive 
expansion is regulated in large part by prolactin receptor (PRLR) signaling39. Moreover, a gene expression anal-
ysis by our group revealed no difference in PRLR expression in WT and Ffar2−/− islets or commonly associated 
downstream genes to the PRLR pathway (Supplementary Table 1); thus, the impaired proliferative response to 
prolactin does not appear to result from impaired gene expression in the PRLR pathway. However, these findings 
Figure 2. Ffar2−/− islets do not demonstrate impaired proliferation, but have increased β cell death. 
 (a) β cell proliferation in WT and Ffar2−/− mice as determined by Ki67 co-localization with insulin-positive 
cells at P1, P21, 10 weeks, and 26 weeks. Bottom: Representative images at P21 shown, scale bar = 20 μ m. Green: 
insulin, red: Ki67. (b) Preproinsulin unmethylation index for WT and Ffar2−/− mice at indicated time points. 
(c) β cell apoptosis in WT and Ffar2−/− mice as determined by cleaved caspase 3 (CC3) staining at P21 and 
10 weeks. Bottom: Representative images at P21 shown. For all experiments, n ≥ 3; white bars = WT, black 
bars = Ffar2−/−. * p < 0.05, * * p < 0.01 and * * * p < 0.001.
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suggest that while there are no apparent differences in proliferation between WT and Ffar2−/− β cells under basal 
conditions, Ffar2−/− β cells may be impaired in their capacity to respond to some proliferative factors, and further 
investigation into the relationship between FFA2 and PRLR signaling is needed.
Gαq/11-biased agonism of FFA2 promotes β cell proliferation. As noted above, acetate did not appear 
to influence β cell proliferation. However, we have previously demonstrated that some FFA2-specific agonists 
demonstrate biased G-protein signaling at mouse FFA2 via either Gα q/11 or Gα i/o pathways28. Because FFA2 cou-
ples to both Gα q/11 and Gα i/o, which have been described to either enhance or inhibit β cell proliferation15,20, 
respectively, we next explored the effect of biased Gα q/11 or Gα i/o signaling via FFA2 on β cell proliferation. 
Assessing the effect of Gα q/11- and Gα i/o-biased FFA2 agonists on β cell proliferation in vitro in the INS1 rat β cell 
line, we found that 48 hours treatment with the Gα q/11-biased agonist 2-butynoic acid (2-BA, previously referred 
to as SCA15), elicited a significant increase in β cell proliferation as determined by BrdU incorporation (Fig. 3b). 
Further, another Gα q/11-biased agonist, 2-propynoic acid (2-PA, previously referred to as SCA14), elicited a con-
siderable, but non-significant increase in β cell proliferation (Fig. 3b). Conversely, treatment with the Gα i/o-biased 
agonist CPTB inhibited β cell proliferation, consistent with a model of Gα q/11-mediated potentiation of β cell 
proliferation and Gα i/o-mediated inhibition of β cell proliferation via FFA2.
To test these observations in a more physiologically relevant model, we conducted an initial screening of the 
Gα q/11-biased compounds in isolated, intact WT islets, and proliferation was assessed by BrdU incorporation. 
Here we found that treatment with 5 mM 2-BA and 0.5 mM cyclopent-1-enecarboxylic acid (CPCA) resulted in a 
substantial increase in β cell proliferation relative to untreated islets (Fig. 3c), while 2-PA, which promoted prolif-
eration in INS1 β cells, had no effect in mouse islets (data not shown). Thus, we next tested CPCA, which elicited 
the largest increase in proliferation in our initial islet studies, in WT and Ffar2−/− islets, and observed a 49% 
increase in proliferation in WT, but not Ffar2−/− islets, demonstrating that this effect is in fact FFA2-dependent 
(Fig. 3d). We further explored the signaling pathways activated by CPCA using in vitro calcium mobilization 
and cAMP accumulation assays, which are indicators of Gα q/11 and Gα i/o signaling pathways, respectively. Here, 
CPCA demonstrated relatively potent calcium mobilization in the BTC3 β cell line, but less potency in the cAMP 
assay, consistent with Gα q/11-biased signaling (Table 1). These data are compared to acetate, which does not affect 
β cell proliferation, and demonstrates higher potency for cAMP inhibition and less potent calcium mobiliza-
tion. Taken together, these data suggest that Gα q/11-biased stimulation of FFA2 by CPCA can promote β cell 
proliferation.
Figure 3. Biased agonism of FFA2 promotes β cell proliferation. (a) β cell proliferation in intact islets from 
WT and Ffar2−/− mice following treatment with prolactin (PRL, 0.5 μ g/ml), Exendin-4 (100 nM), and acetate 
(1 mM). (b) β cell proliferation in INS1 cells following treatment with prolactin (PRL, 0.5 μ g/ml), acetate 
(AcO, 1 mM), 2-propynoic acid (2-PA, 0.5 mM), 2-butynoic acid (2-BA, 5 mM), cyclopent-1-enecarboxylic 
acid (CPCA, 0.5 mM), or CPTB (5 μ M), as determined by flow cytometry. (c) β cell proliferation in intact WT 
islets following treatment with placental lactogen (PL, 0.5 μ g/ml), acetate (AcO, 1 mM), 2-butynoic acid (2-BA, 
5 mM), or cyclopent-1-enecarboxylic acid (CPCA, 0.5 mM). (d) β cell proliferation in intact islets from WT and 
Ffar2−/− mice following treatment with CPCA (0.5 mM). For all experiments, n = 3. * p < 0.05, * * p < 0.01 and  
* * * p < 0.001. For a and d, white bars represent WT, black barsrepresent Ffar2−/−.
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Discussion
Growing evidence that the loss of functional β cell mass is a primary mechanism of T2D pathogenesis sug-
gests that the identification of novel targets that promote β cell growth, proliferation, and survival may be espe-
cially desirable targets for early disease intervention. Thus, here we assessed the role of FFA2 in regulating β cell 
mass. We observed impaired β cell mass at birth, and throughout adulthood in Ffar2−/− mice. In vitro assays 
of β cell proliferation in WT and Ffar2−/− islets did not reveal any intrinsic differences in proliferation at base-
line in Ffar2−/− β cells, nor in their response to the GLP1 receptor agonist Exendin 4, but our data did suggest 
that Ffar2−/− islets may be compromised in their ability to respond to prolactin. This raises the possibility that 
Ffar2−/− mice may experience a developmental impairment arising from decreased sensitivity to developmental 
signaling factors. Interestingly, we have previously reported impaired β cell mass expansion and glucose tolerance 
in Ffar2−/− female mice during pregnancy. As prolactin is a major driver of β cell mass expansion during preg-
nancy39,40, these data further point to the relationship between PRLR and FFA2 signaling as an important future 
avenue of inquiry.
Surprisingly, at 21 days of age, Ffar2−/− mice exhibit increased β cell proliferation, which appears to be sec-
ondary to a large increase in β cell death, which is detectable until at least 10 weeks of age. These observations 
suggest that FFA2 also contributes to supporting β cell survival during adolescence and early adulthood. It is 
noteworthy that despite our observations of diminished β cell mass in Ffar2−/− mice, we have previously reported 
that these mice do not exhibit any overt metabolic phenotype in vivo28. However, we have observed that isolated 
Ffar2−/− islets secrete significantly less insulin than WT islets in response to stimuli such as high glucose and 
the GLP-1 receptor agonist, Exendin-428. Taken together, these data suggest that in our mouse model, sufficient 
compensation occurs to maintain overall glucose homeostasis in Ffar2−/− mice, despite impaired GSIS in vitro 
and diminished β cell mass.
Notably, two other groups have recently published their findings regarding the effect of Ffar2 deletion on β 
cell function29,30. While Tang et al.30 reported no morphological differences in the islets of their WT and Ffar2−/− 
mice, it is significant that they did not conduct de facto β cell mass or area analysis. More significantly, McNelis 
et al.29, did not identify any impairments in β cell area from Ffar2−/− mice under normal diet conditions, although 
they did observe impaired adaptive β cell mass expansion in Ffar2−/− mice on HFD, along with impaired glucose 
tolerance. In their mouse model, these impairments stemmed from a failure of Ffar2−/− β cells to proliferate. In 
our studies, we observed a notable, but not significant defect in β cell proliferation following 1 week HFD or 20 
weeks of HFD in Ffar2−/− mice (Supplementary Fig. 1). However, our analyses were conducted very early and 
very late in insulin resistance (1 week and 20 weeks, respectively), and may have missed the window of maximal 
compensatory β cell proliferation. Moreover, it has been noted that the phenotype elicited by HFD can vary 
greatly, depending on factors such as the genetic background, the diet’s micro- and macronutrient composition, 
and the timing of high fat-feeding41.
Because expansion of β cell mass is a critical component of islet adaptation to insulin resistance and the main-
tenance of glucose homeostasis, methods to promote β cell growth and proliferation offer invaluable therapeutic 
tools for T2D. As we previously reported, some FFA2 agonists demonstrate signaling bias, preferentially signaling 
through Gα i/o or Gα q/11, which results in differential effects on GSIS28. Likewise, our data here suggest that these 
differential effects may extend to the regulation of β cell proliferation. Encouragingly, our studies suggest that 
FFA2 may be a novel target to promote β cell proliferation and survival. As the in vivo metabolism and toxicity of 
these FFA2 agonists is unknown, the compounds are currently unsuitable for additional experimentation, thus, 
additional work is underway to develop new Gα q/11-biased FFA2 agonists that are more suitable for in vivo use. 
However, in vitro and ex vivo testing of these agonists have demonstrated the potential of Gα q/11-biased FFA2 to 
substantially increase β cell proliferation in intact islets. These studies are in agreement with the recent report by 
McNelis et al., who observed a statistically significant increase in β cell proliferation following treatment with the 
phenylacetamide agonist PA1, which they reported to be primarily Gα q/11-mediated. Taken together, these two 
independent studies point to FFA2 as a potential target to promote β cell proliferation.
It is especially noteworthy that we have previously observed PA1 (referred to herein as CPTB), to be primarily 
Gα i/o-biased, while the publication by McNelis et al., suggests a Gα q/11-biased signaling mechanism. Accordingly, 
while McNelis et al. report PA1-mediated increases in β cell proliferation and insulin secretion, we have observed 
PA1-mediated inhibition of β cell proliferation and insulin secretion. As discussed in recent studies of FFA228–30,42,43, 
these discrepancies may result from the use of different mouse models made by different methods and on dif-
ferent backgrounds. Other factors may contribute to the widely varying phenotypes observed across multiple 
studies. Specifically, GPCR coupling can be regulated by numerous factors, for example by dimerization with 
other receptors44 or interaction with modifying proteins45, both of which may be modulated by the physiologic 
state of the host. Given the apparent complexity of FFA2 signaling and the Ffar2−/− phenotype, it is critical that 
we develop a deeper understanding of how FFA2 signaling and coupling is regulated. Considering FFA2’s role as a 
CPCA Acetate
Calcium EC50
7.8 ± 0.4 2.3 ± 0.2
(n = 3) (n = 13)
cAMP EC50
2.7 ± 0.4 4.4 ± 0.2
(n = 4) (n = 6)
Table 1. Signaling properties of the FFA2 agonist CPCA. pEC50 of CPCA in calcium mobilization and cAMP 
accumulation assays is shown. Acetate values shown for comparison. Values are mean ± SEM.
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nutrient sensor, future studies aimed at understanding what factors underlie the regulation of FFA2 coupling and 
signaling in different physiologic and biochemical states will be of particular importance in helping to guide the 
development of FFA2 into a viable therapeutic target for T2D.
Methods
Animals. Heterozygous Ffar2 knockout mice (Ffar2+/−) on a C57BL/6J background were crossed to pro-
duce Ffar2 wild-type (WT) and Ffar2 knockout (Ffar2−/−) mice. Genotypes were determined as previously 
described42. Mice were housed in a temperature-controlled facility with 12-hour light-dark cycle, and given ad 
libitum access to water and normal (LM-485, Harlan Laboratories, Indianapolis, IN) or high fat chow (TD.06414, 
Harlan Laboratories, started at 6 or 10 weeks of age). All experiments described in this report were carried out 
in accordance with protocols approved by the Institutional Animal Care and Use Committee at Northwestern 
University.
Tissue processing, immunolabeling, and morphometric analysis. Mouse pancreata were imme-
diately removed from euthanized mice, weighed, and fixed in 4% paraformaldehyde in 1X PBS for 1 hour 
and kept in 30% sucrose in PBS overnight. The next day, pancreata were cryopreserved by embedding in 
optimal-cutting-temperature compound and stored at − 80 °C until further processing. Pancreata were sectioned 
at 7 μ m using a microtome-cryostat. For morphometric analysis, three to four non-overlapping sections from 
each pancreas (spanning the width of the pancreas) were used for each analysis. All analyses were conducted on 
at least 3 animals per age, genotype, and treatment condition.
For determination of β cell mass, sections were immunolabeled with guinea pig anti-insulin and rabbit 
anti-glucagon primary antibodies and imaged by epifluorescence at 4X and 40X magnification. The total pancre-
atic area and insulin positive area of each section was measured using ImageJ software (http://imagej.nih.gov/ij/). 
β cell mass was estimated as the product of the relative β cell area and the wet weight of the pancreas.
β cell proliferation was examined by immunolabeling with guinea pig anti-insulin and rabbit anti-Ki67 pri-
mary antibodies. Islets were imaged at 40X, and the number of insulin-positive and insulin- and Ki67-positive 
cells counted, and proliferation was calculated as the percentage of Ki67-positive β cells.
β cell apoptosis was examined by immunolabeling with guinea pig anti-insulin and rabbit anti-cleaved caspase 
3 primary antibodies. Islets were imaged at 40X, and the number of insulin-positive cells counted. Cleaved 
caspase 3-positive cells were counted as apoptotic islet cells if they co-localized with insulin, or were located 
within the insulin-positive islet area.
The following primary antibodies were used, all diluted in antibody diluent buffer (Dako, Carpinteria, CA): 
guinea pig anti-insulin (1:200; Abcam, Cambridge, MA), rabbit anti-glucagon (1:200; Cell Signaling, Danvers, 
MA), rabbit anti-Ki67 (1:100; Cell Signaling), rabbit anti-cleaved caspase 3 (1:2000, Abcam, Cambridge, MA). 
Goat-derived secondary antibodies conjugated to Fluorescein or Texas Red were used at 1:200 dilution (Vector 
Laboratories, Burlingame, CA). All slides were mounted with Vectashield with DAPI (Vector Laboratories).
Islet isolation and culture. Islets were isolated by collagenase digestion as previously described28. Following 
isolation, islets were handpicked under a dissection microscope and left to recover overnight at 37 °C in RPMI 
1640 supplemented with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin.
In vitro β cell proliferation assay. INS1 cells were cultured and maintained as previously described46. Cells 
were seeded at a density of 106 in a 60 mm dish and incubated overnight at 37 °C. The following day, cells were 
either maintained in culture media (control) or treated with the indicated agonist for 48 hours prior to analysis by 
flow cytometry. After the first 24 hour treatment period, BrdU was added to culture media at a concentration of 
0.1 mg/ml. Following 48 hours of agonist treatment, cells were fixed, permeabilized, and labeled with anti-BrdU 
antibody using a FITC BrdU Flow Kit purchased from BD Pharmingen (San Jose, CA), according to the man-
ufacturer’s protocol. Cells were counted by flow cytometry, with a minimum of 30,000 events counted at a rate 
of no more than 400 events per second. Dead and apoptotic cells were excluded from counts by Annexin V and 
propidium iodide staining.
Ex vivo β cell proliferation assay. β cell proliferation was assessed by two separate methods. First, a 
blinded, small-scale ex vivo assay was performed on intact islets isolated from WT mice as previously described47. 
Compounds were initially screened at multiple concentrations (0.1–5 mM) to assess dose-response. Subsequent 
experiments were carried out with acetate, 2-BA, and CPCA at the indicated concentrations, as determined by 
dose response curve. Placental lactogen (PL) at 0.5 ug/ml served as a positive control for β cell proliferation38. 
β cell proliferation was visualized by insulin and Ki67 immunolabeling in mildly dissociated islets. Slides were 
scanned using an Aperio ScanScope FL scanner and images processed as previously described48.
Second, proliferation was assessed by 5-bromo-2-deoxyuridine (BrdU) incorporation as previously described 
with slight modifications49. WT and Ffar2−/− islets were cultured for 4 days with media supplemented with or 
without prolactin (500 ng/mL); Exendin-4 (100 nM) or acetate (1 mM). The media was changed every second 
day. 500 ng/mL BrdU (Sigma) was added to the culture media during the last 24 hours. Islets were dispersed 
with 0.05% trypsin and fixed on poly-L-lysine coated coverslips with 4% paraformaldehyde. Epitopes were 
retrieved by treatment with 1N hydrochloric acid for 25 minutes at 37 °C. Immunostaining of BrdU and insulin 
was performed on processed islets, and β -cell proliferation rate was determined by quantifying percentage of 
BrdU-positive insulin-positive cells. Following antibodies were used: primary-rat anti-BrdU (1:100, Abcam), 
guinea pig anti-insulin (1:100, Abcam); secondary-FITC goat anti-guinea pig IgG (1:200) (Vector Laboratories), 
AlexaFluor-594 goat anti-rat IgG (1:200, Life Technologies, Madison, WI).
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Differential methylation analysis. Differentially methylated insulin DNA was measured by multiplex 
PCR analysis using terminal serum collected from 4–5 animals per age and genotype as previously described34. 
Unmethylation index is the ratio of unmethylated preproinsulin DNA to methylated preproinsulin DNA in 
serum.
Assessment of Ca2+ mobilization and cAMP accumulation by FFA2. Calcium mobilization was 
assessed in the β TC3 mouse β cell line, a cell line that does not express FFA3, a related receptor28. Cells were 
seeded overnight and serum starved in a 96-well black wall/clear bottom plate. On the day of the experiment, 
cells were loaded with 5 μ M Fluo-8 (AAT Bioquest, Sunnyvale, CA) and incubated at 37 °C for 60 minutes. 
Compounds were next titrated at multiple concentrations and fluorescence was measured using a fluorometric 
imaging plate reader (FLIPR). For cAMP assays, CHO-K1 cells were transfected with an expression vector con-
taining full-length human FFA2 cDNA (GenBank Accession Number NM_005306) with FLAG tag sequence at 
N-terminus, and assays performed as previously described50. This assay was performed at Multispan, Inc. In each 
experiment, each compound was tested in quadruplicate at multiple concentrations. The pEmax and pEC50 were 
obtained for each compound based on concentration-response curves generated using GraphPad Prism.
RNA-seq and data analysis. Total cellular RNA was extracted from isolated islets (pooled from 2 mice) 
using an RNeasy Mini kit (QIAGEN, Venlo, Linburg). Experiments were run in triplicate for each genotype. RNA 
seq and data analyses were carried out by the Next Generation Sequencing Core, Center for Genetic Medicine, 
Northwestern University. Briefly, alignment and expression analysis were performed using TopHat (v2.0.8b) and 
Cufflinks (v2.1.1). Differential expression was determined by cuffdiff using an FDR cutoff value of 0.05. The 
results of the differential expression analysis were processed with the R package, cummerbund (http://compbio.
mit.edu/cummeRbund/) to obtain up-and down-regulated genes.
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